Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats

Eur J Pharmacol. 2011 Nov 16;670(1):216-23. doi: 10.1016/j.ejphar.2011.08.048. Epub 2011 Sep 14.

Abstract

The therapeutic potential of cannabidiol, the major non-psychotropic Cannabis constituent, was investigated in rats exposed to ischemia/reperfusion liver injury. Ischemia was induced by clamping the pedicle of the left hepatic lobe for 30 min, and cannabidiol (5mg/kg, i.v.) was given 1h following the procedure and every 24h thereafter for 2 days. Ischemia/reperfusion caused significant elevations of serum alanine aminotransferase and hepatic malondialdehyde, tumor necrosis factor-α and nitric oxide levels, associated with significant decrease in hepatic reduced glutathione. Cannabidiol significantly attenuated the deterioration in the measured biochemical parameters mediated by ischemia/reperfusion. Histopathological examination showed that cannabidiol ameliorated ischemia/reperfusion-induced liver damage. Immunohistochemical analysis revealed that cannabidiol significantly reduced the expression of inducible nitric oxide synthase, cyclooxygenase-2, nuclear factor-κB, Fas ligand and caspase-3, and increased the expression of survivin protein in ischemic/reperfused liver tissue. These results emphasize that cannabidiol represents a potential therapeutic option to protect the liver against hypoxia-reoxygenation injury.

MeSH terms

  • Alanine Transaminase / blood
  • Animals
  • Cannabidiol / administration & dosage
  • Cannabidiol / pharmacology*
  • Cannabidiol / therapeutic use*
  • Liver / drug effects
  • Liver / injuries*
  • Liver / metabolism
  • Liver / pathology
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Reperfusion Injury / blood
  • Reperfusion Injury / drug therapy*
  • Reperfusion Injury / pathology
  • Reperfusion Injury / prevention & control*
  • Time Factors

Substances

  • Cannabidiol
  • Alanine Transaminase